Gloucester Pharmaceuticals’ Istodax® (romidepsin) Receives FDA Approval to Treat Cutaneous T-cell Lymphoma

I am pleased to announce that my partner and co-founder, Jay Mohr, Managing Director of Locust Walk Partners, recently achieved a professional milestone.  Jay was founding CEO of Gloucester Pharmaceuticals and was responsible for diligencing and in-licensing Istodax® from Fujisawa (now Astellas).